aztreonam has been researched along with Infectious Skin Diseases in 7 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aztreonam was used in the initial treatment of infection of the urinary tract (23 cases), respiratory tract (17 cases), skin and soft tissue (12 cases), abdominal cavity (three cases), endocarditis (two cases), septicemia (eight cases), and osteomyelitis (two cases)." | 5.27 | Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections. ( Chandrasekar, P; Kannangara, W; LeFrock, JL; Molavi, A; Rolston, KV; Smith, BR, 1987) |
| "Multicenter trials were conducted to determine the safety and efficacy of aztreonam in the treatment of patients with gram-negative bacterial infections." | 5.05 | Aztreonam: worldwide overview of the treatment of patients with gram-negative infections. ( Bendush, CB; Henry, SA, 1985) |
| "Linezolid therapy was associated with improved clinical outcomes and significantly lower treatment costs than was vancomycin." | 2.72 | Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. ( Itani, KM; Liu, LZ; McKinnon, PS; Sorensen, SV, 2006) |
| " Dosage of aztreonam was 2 to 8 g per day administered intravenously or intramuscularly for five to 52 days." | 2.66 | Aztreonam in the treatment of serious orthopedic infections. ( Beskin, J; Beville, R; Haddad, RJ; Holmes, B; Mogabgab, WJ; Pollock, B; Pribyl, C; Salzer, R, 1985) |
| "Aztreonam was used in the initial treatment of infection of the urinary tract (23 cases), respiratory tract (17 cases), skin and soft tissue (12 cases), abdominal cavity (three cases), endocarditis (two cases), septicemia (eight cases), and osteomyelitis (two cases)." | 1.27 | Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections. ( Chandrasekar, P; Kannangara, W; LeFrock, JL; Molavi, A; Rolston, KV; Smith, BR, 1987) |
| "Aztreonam was well tolerated." | 1.27 | Treatment of gram-negative infections with aztreonam. ( Lee, TJ; Simons, WJ, 1985) |
| "Aztreonam is a monocyclic beta-lactam antibiotic that inhibits aerobic gram-negative bacilli, including beta-lactamase-producing species." | 1.27 | Current state of infectious diseases--potential areas of directed therapy with aztreonam. ( Neu, HC, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (71.43) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McKinnon, PS | 1 |
| Sorensen, SV | 1 |
| Liu, LZ | 1 |
| Itani, KM | 1 |
| Talbot, GH | 1 |
| Thye, D | 1 |
| Das, A | 1 |
| Ge, Y | 1 |
| LeFrock, JL | 1 |
| Smith, BR | 1 |
| Chandrasekar, P | 1 |
| Rolston, KV | 1 |
| Molavi, A | 1 |
| Kannangara, W | 1 |
| Pribyl, C | 1 |
| Salzer, R | 1 |
| Beskin, J | 1 |
| Haddad, RJ | 1 |
| Pollock, B | 1 |
| Beville, R | 1 |
| Holmes, B | 1 |
| Mogabgab, WJ | 1 |
| Henry, SA | 1 |
| Bendush, CB | 1 |
| Simons, WJ | 1 |
| Lee, TJ | 1 |
| Neu, HC | 1 |
4 trials available for aztreonam and Infectious Skin Diseases
| Article | Year |
|---|---|
Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
Topics: Acetamides; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Clinical Trials as | 2006 |
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Female; Humans; Male; Methicil | 2007 |
Aztreonam in the treatment of serious orthopedic infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infections; Clinical | 1985 |
Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.
Topics: Abdomen; Adult; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infections; Clini | 1985 |
3 other studies available for aztreonam and Infectious Skin Diseases
| Article | Year |
|---|---|
Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections.
Topics: Adult; Aged; Aged, 80 and over; Aztreonam; Bacterial Infections; Female; Gram-Negative Bacteria; Hum | 1987 |
Treatment of gram-negative infections with aztreonam.
Topics: Abscess; Adult; Aged; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infections; | 1985 |
Current state of infectious diseases--potential areas of directed therapy with aztreonam.
Topics: Abdomen; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infections; Biliary Trac | 1985 |